Evidence map›Paper›PMID 37719371›Full record

ArticleActa pharmaceutica Sinica. B2023

Amelioration of ethanol-induced oxidative stress and alcoholic liver disease by

Yalan Wang, Qiubing Chen, Shuang Wu, Xinyu Sun, Runting Yin, Zhen Ouyang, Hao Yin, Yuan Wei

Abstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Lipid nanoparticle delivery of siRNA targetingZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yalan WangSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Qiubing ChenDepartment of Urology, Frontier Science Centre for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Shuang WuSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Xinyu SunSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Runting YinSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Zhen OuyangSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.
Hao YinDepartment of Urology, Frontier Science Centre for Immunology and Metabolism, Medical Research Institute, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan 430071, China.
Yuan WeiSchool of Pharmacy, Jiangsu University, Zhenjiang 212013, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Alcoholic liver disease (ALD) results from continuous and heavy alcohol consumption. The current treatment strategy for ALD is based on alcohol withdrawal coupled with antioxidant drug intervention, which is a long process with poor efficacy and low patient compliance. Alcohol-induced CYP2E1 upregulation has been demonstrated as a key regulator of ALD, but

Indexed as

Alcoholic liver diseaseCyp2e1Lipid nanoparticleLipogenesisLipometabolismOxidative stressReactive oxygen speciesRNAi

Identifiers

PMID37719371
PMCPMC10502278

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.